Mitochondria damage in the pathogenesis of diabetic retinopathy and in the metabolic memory associated with its continued progression

Current Medicinal Chemistry

Volumn 20, Issue 26, 2013, Pages 3226-3233

  Kowluru, Renu A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Diabetic retinopathy; Epigenetic modifications; Mitochondria damage; Mitochondria DNA; Oxidative stress

Indexed keywords

BENFOTIAMINE; CASPASE 3; CELL NUCLEUS DNA; CYTOCHROME C OXIDASE; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; THIOCTIC ACID;

APOPTOSIS; ARTICLE; BIOGENESIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA METHYLATION; ENDOTHELIUM CELL; EPIGENETICS; GLYCEMIC CONTROL; HUMAN; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS;

ANIMALS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; EPIGENOMICS; HUMANS; HYPERGLYCEMIA; MITOCHONDRIA;

EID: 84883246730     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990029     Document Type: Article

References (99)

1. Calcutt, N.A.; Cooper, M.E.; Kern, T.S.; Schmidt, A.M. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat. Rev. Drug. Discov., 2009, 8, 417-429.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of long-Term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993, 329, 977-986.
3. Frank, R.N. Diabetic Retinopathy. N. Engl. J. Med., 2004, 350, 48-358.
4. Klein, R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 1995, 18, 258-268.
5. Klein, R.; Klein, B.E.; Jensen, S.C.; Moss, S.E. The relation of socioeconomic factors to the incidence of proliferative diabetic retinopathy and loss of vision. Ophthalmology, 1994, 101, 68-76.
6. Yau, J.W.; Rogers, S.L.; Lamoureux, E.L.; Kowalski, J.W.; Bek, T.; Chen, S.J.; Dekker, J.M.; Fletcher, A.; Grauslund, J.; Haffner, S.; Hamman, R.F.; Ikram, M.K.; Kayama, T.; Klein, B.E.; Klein, R.; Krishnaiah, S.; Mayurasakorn, K.; O'Hare, J.P.; Orchard, T.J.; Porta, M.; Rema, M.; Roy, M.S.; Sharma, T.; Shaw, J.; Taylor, H.; Tielsch, J.M.; Varma, R.; Wang, J.J.; Wang, N.; West, S.; Xu, L.; Yasuda, M.; Zhang, X.; Mitchell, P.; Wong, T.Y. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012, 35, 556-564.
7. Wong, T.Y.; Yau, J.; Rogers.; S, Kawasaki, R.; Lamoureux, E.L. Global Prevalence of Diabetic Retinopathy: Pooled Data from Population Studies from the United States, Australia, Europe and Asia. Invest. Ophtahlmol. Vis. Sci., 2011, Abstract# 4818.
8. Whiting, D.R.; Guariguata, L.; Weil, C.; Shaw, J. IDF diabetes atlas: global estimates of the prevalence. Diabees. Res. Clin. Pract., 2011, 94, 311-321.
9. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N.Engl. J. Med., 2000, 42, 381-389.
10. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA., 2002, 287, 2563-2569.
11. Klein, R.; Klein, B.E.; Moss, S.E.; Davis, M.D.; DeMets, D.L. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. I. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol., 1984, 102, 520-526.
12. Dodson, P.M. Management of diabetic retinopathy: could lipidlowering be a worthwhile treatment modality? Eye (Lond). 2009, 23, 997-1003.
13. Silva, K.C.; Rosales, A.; Biswas, S.K.; Lopes de Faria, J.B.; Lopes de Faria, J.M. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes, 2009, 58, 382-1390.
14. Engerman, R.L. Pathogenesis of diabetic retinopathy. Diabetes, 1989, 38, 1203-1206.
15. Barber, A.J.; Lieth, E.; Khin, S.A.; Antonetti, D.A.; Buchanan, A.G.; Gardner, T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest., 1998, 102, 783-791.
16. Kern, T.S.; Tang, J.; Mizutani, M.; Kowluru, R.; Nagraj, R.; Lorenzi, M. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: Comparison of diabetes and galactosemia. Invest. Ophthalmol. Vis. Sci., 2000, 41, 3972-3978.
17. Mizutani, M.; Gerhardinger, C.; Lorenzi, M. Muller cell changes in human diabetic retinopathy. Diabetes. 1998, 47, 455-459.
18. Mizutani, M.; Kern, T.S.; Lorenzi, M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J. Clin. Invest., 1996, 97, 2883-2890.
19. Santos, J.M.; Mohammad, G.; Zhong, Q.; Kowluru, R.A. Diabetic retinopathy, superoxide damage and antioxidant. Curr. Pharm. Biotechnol., 2011, 12, 352-3561.
20. Simó, R.; Hernández, C. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br. J.Ophthalmol., 2012, 96, A1285-1290.
21. Kowluru, R.A.; Chan, P.S. Oxidative stress and diabetic retinopathy. Exp. Diabetes. Res. 2007, 2007, 43603.
22. Kowluru, R.A.; Zhong, Q. Beyond AREDS: Is there a place for anti-oxidant therapy in the prevention/ treatment of eye disease? Invest Ophthalmol. Vis. Sci., 2011, 52, 8665-8671.
23. Robinson, R.; Barathi, V.A.; Chaurasia, S.S.; Wong, T.Y.; Kern, T.S. Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis. Model. Mech., 2012, 5, 444-446.
24. Baynes, J.W.; Thrope, S.R. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes, 1999, 48, 1-9.
25. Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 2005, 54, 615-1625.
26. Kowluru, R.A.; Jirousek, M.R.; Stramm, L.E.; Farid, N.A.; Engerman, R.L.; Kern, T.S. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases. Diabetes, 1998, 47, 464-469.
27. Nicholls, D. Mitochondrial bioenergetics, aging, and aging-related disease. Sci. Aging Knowledge. Environ., 2002, 2002, pe12.
28. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug. Discov., 2010, 9, 447-464.
29. Morán, M.; Moreno-Lastres, D.; Marín-Buera, L.; Arenas, J.; Martín, M.A.; Ugalde, C. Mitochondrial respiratory chain dysfunction: implications in neurodegeneration. Free Radic. Biol. Med., 2012, 53, 595-609.
30. Vafai, S.B.; Mootha, V.K.; Mitochondrial disorders as windows into an ancient organelle. Nature, 2012, 491, 374-383.
31. Ray, P.D.; Huang, B.W.; Tsuji, Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal, 2012, 24, 981-990.
32. Kowluru, R.A. Diabetic retinopathy: Mitochondrial dysfunction and retinal capillary cell death. Antioxid. Redox. Sign., 2005, 7,1581-1587.
33. Kowluru, R.A.; Abbas, S.N. Diabetes-induced mitochondrial dysfunction in the retina. Inves Ophthalmol. Vis. Sci., 2003, 44, 5327-5334.
34. Kanwar, M.; Chan, P.S.; Kern, T.S.; Kowluru, R.A. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest. Ophthalmol. Vis. Sci., 2007, 48, 3805-3811.
35. Trudea, K.; Molina, A.J.; Guo, W.; Roy, S. High glucose disrupts mitochondrial morphology in retinal endothelial cells: implications for diabetic retinopathy. Am. J. Path., 2010, 177, 447-455.
36. Barnes, D.E. DNA damage: air-breaks. Curr. Biol., 2002, 12, R262-R264.
37. Chen, X.J.; Butow, R.A. The organization and inheritance of the mitochondrial genome. Nat. Rev. Genet., 2005, 6, 815-25.
38. Kucej, M.; Kucejova, B.; Subramanian, R.; Chen, X.J.; Butow, R.A. Mitochondrial nucleoids undergo remodeling in response to metabolic cues. J. Cell. Sci., 2008, 121,1861-1868.
39. Wanrooij, S.; Falkenberg, M. The human mitochondrial replication fork in health and disease. Biochim. Biophys. Acta., 2010,1797, 1378-1388.
40. Stuart, J.A.; Brown, M.F. Mitochondrial DNA maintenance and bioenergetics. Biochim Biophys. Acta., 2006, 1757,79-89.
41. Sastre, J.; Pallardó, F.V.; Viña, J. The role of mitochondrial oxidative stress in aging. Free. Radic. Biol. Med., 2003, 35,1-8.
42. Van Houten, B.; Woshner, V.; Santos, J.H. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair, 2005, 5,145-152.
43. Santos, J.M.; Tewari, S.; Kowluru, R.A. A compensatory mechanism protects retinal mitochondria from initial insult in diabetic retinopathy. Free Rad. Biol. Med., 2012, 53, 1729-1737.
44. Madsen-Bouterse, S.A.; Mohammad, G.; Kanwar, M.; Kowluru, R.A. Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxid. Redox Signal, 2010, 13,797-805.
45. Madsen-Bouterse, S. Zhong, Q. Mohammad, G.; Ho, Y.S.; Kowluru, R.A. Oxidative damage of mitochondrial DNA in diabetes, and its protection by manganese superoxide dismutase. Free Rad. Research., 2010, 44, 313-321.
46. Santos, J.M.; Kowluru, R.A. Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 2011, 52, 8791-8798.
47. Santos, J.M.; Tewari, S.; Goldberg, A.F.X.; Kowluru, R.A. Mitochondria biogenesis and the development of diabetic retinopathy. Free Rad. Biol. Med., 2011, 51, 1849-1860.
48. Scarpulla, R.C. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann. N Y. Acad. Sci., 2008, 1147, 321-334.
49. Scarpulla, R.C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev., 2008, 88, 611-638.
50. Tewari, S.; Santos, J.M.; Kowluru, R.A. Damaged mitochondrial DNA replication system and the development of diabetic retinopathy. Antioxid. Redox. Signal., 2012, 17, 492-504.
51. Tewari, S.; Zhong, Q.; Santos, J.M.; Kowluru, R.A. Mitochondria DNA replication and DNA methylation in the metabolic memory associated with continued progression of diabetic retinopathy. Inves Ophthalmol. Vis. Sci., 2012, 53, 4881-4888.
52. Clayton, D.A. Transcription and replication of mitochondrial DNA. Hum, Reprod., 2000, 15, 11-17.
53. Rothfuss, O.; Gasser, T.; Patenge, N. Analysis of differential DNA damage in the mitochondrial genome employing a semi-long run real-Time PCR approach. Nucleic Acids Res., 2010, 38, e24.
54. Miyazono, F.; Schneider, P.M.; Metzger, R.; Warnecke-Eberz, U.; Baldus, S.E.; Dienes, HP.; Aikou, T.; Hoelscherm A.H. Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett's esophagus. Oncogene, 2002, 21, 3780-3783.
55. Sharma, H.; Singh, A.; Sharma, C.; Jain, S.K.; Singh, N. Mutations in the mitochondrial DNA D-loop region are frequent in cervical cancer. Cancer. Cell. Int., 2005, 5, 34.
56. Schultz, R.A.; Swoap, S.J.; McDaniel, L.D.; Zhang, B.; Koon, E.C.; Garry, D.J.; Li, K.; Williams, R.S. Differential expression of mitochondrial DNA replication factors in mammalian tissues. J. Biol. Chem., 1998, 27, 3447-3451.
57. Korhonen, J.A.; Pham, X.H.; Pellegrini, M.; Falkenberg, M. Reconstitution of a minimal mtDNA replisome in vitro. EMBO J., 2004, 23, 2423-2429.
58. Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the diabetes control and complication trial. Arch. Ophthalm., 1998, 116, 874-886.
59. White, N.H.; Sun, W.; Cleary, P.A.; Danis, R.P.; Davis, M.D.; Hainsworth, D.P. Hubbard, L.D.; Lachin, J.M.; Nathan, D.M. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch. Ophthalmol., 2008, 126,1707-1715.
60. White, N.H.; Sun, W.; Cleary, P.A.; Tamborlane, W.W.; Danis, R.P.; Hainsworth, D.P. Davis, M.D.; DCCT-EDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes, 2010, 59,1244-1253.
61. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 1998, 352, 837-853.
62. Engerman, R.L.; Kern, T.S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes, 1987, 36, 808-812.
63. Hammes, H-P.; Klinzing, I.; Wiegand, S.; Bretzel, R.G.; Cohen, A.M.; Federlin, K. Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen diabetic rat. Invest Ophthalmol. Vis. Sci., 1993, 34, 2092-2096.
64. Kowluru, R.A. Effect of re-institution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes, 2003, 52, 818-823.
65. Kowluru, R.A.; Abbas, S.N.; Odenbach, S. Effect of re-institution of good metabolic control on oxidative stress in the kidney of diabetic rats. J. Diabetes & its Complications, 2004, 18, 82-288.
66. Kowluru, R.A.; Chan, P.S. Metabolic memory in diabetes-from in vitro oddity to in vivo problem: Role of Apoptosis. Brain. Res. Bull., 2010, 87, 297-302.
67. Zhong, Q.; Kowluru, R.A. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J. Cell. Biochem., 2010, 110,1306-1313.
68. Zhong, Q.; Kowluru, R.A. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes, 2011, 60,1304-1313.
69. Zhong, Q.; Kowluru R.A. Diabetic retinopathy and damage to mitochondrial structure and transport machinery. Inves Ophthalmol. Vis. Sci., 2011, 52, 8739-8746.
70. Engerman, R.L.; Kern, T.S. Retinopathy in galactose-fed dogs continues to progress after cessation of galactosemia. Arch. Ophthalmol., 1995, 113, 355-358.
71. Roy, S.; Sala, R.; Cagliero, E.; Lorenzi, M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc. Natl. Acad. Sci. USA., 1990, 87, 404-408.
72. Kowluru, R.A.; Zhong, Q.; Kanwar, M. Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp. Eye Res., 2010, 90, 617-623.
73. Madsen-Bouterse, S.A.; Kowluru, R.A. Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Rev. Endocr. Metab. Disord., 2008, 9, 315-327.
74. Zhong, Q.; Kowluru, R.A. Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: Role of histone methylation. Invest. Ophthalmol. Vis. Sci., 2013, 54, 244-250.
75. Zhong, Q.; Kowluru, R.A. Regulation of matrix metallopeptidase-9 by epigenetic modifications, and the development of diabetic retinopathy. Diabetes, 2013, 62, 2559-2568.
76. Genuth, S.; Sun, W.; Cleary, P.; Sell, D.R.; Dahms, W.; Malone, J.; Sivitz, W.; Monnier, V.M.; DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes, 2005, 54, 3103-3111.
77. Kowluru, R.A.; Chakrabarti, S.; Chen, S. Re-Institution of good metabolic control in diabetic rats on the activation of caspase-3 and nuclear transcriptional factor (NF-kB) in the retina. Acta Diabetologica, 2004, 44, 194-199.
78. Tristan, C.; Shahani, N.; Sedlak, T.W.; Sawa, A. The diverse functions of GAPDH: views from different subcellular compartments. Cell Signal, 2011, 23, 317-323.
79. Du, X.; Matsumura, T.; Edelstein, D.; Rossetti, L.; Zsengeller, Z.; Szabo, C.; Brownlee, M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest., 2003, 112, 1049-1057.
80. Kanwar, M.; Kowluru, R. Role of glyceraldehyde 3-phosphate dehydrogenase in the development and progression of diabetic retinopathy. Diabetes, 2009, 58, 227-234.
81. Ross, S.A.; Milner, J.A. Epigenetic modulation and cancer: effect of metabolic syndrome? Am. J. Clin. Nutr., 2007, 86, 872-877.
82. Zhang, T.Y.; Meaney, M.J. Epigenetics and the environmental regulation of the genome and its function. Annu. Rev. Psychol., 2010, 61, 439-466.
83. Feil, R.; Fraga, M.F. Epigenetics and the environment: emerging patterns and implications. Nat. Rev. Genet., 2012, 13, 97-109.
84. Teegarden, D.; Romieu, I.; Lelièvre, S.A. Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved? Nut. Res. Rev., 2012, 25, 68-95.
85. Lazarou, C.; Panagiotakos, D.; Matalas, A.L. The role of diet in prevention and management of type 2 diabetes: implications for public health. Crit. Rev. Food. Sci. Nutr., 2012, 52, 382-389.
86. Brasacchio, D.; Okabe, J.; Tikellis, C.; Balcerczyk, A.; George, O.; Baker, E.K.; Calkin, A.C.; Brownlee, M.; Cooper, M.E.; El-Osta, A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with geneactivating epigenetic marks that coexist on the lysine tail. Diabetes, 2009, 58, 1229-1236.
87. El-Osta, A.; Brasacchio, D.; Yao, D.; Pocai, A.; Jones, P.L.; Roeder, R.G. Cooper, M.E.; Brownlee, M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med., 2008, 205, 2409-2417.
88. Cooper, M.E.; El-Osta, A. Epigenetics: mechanisms and implications for diabetic complications. Circ. Res., 2010, 107,1403-1413.
89. Villeneuve, L.M.; Reddy, M.A.; Natarajan, R. Epigenetics: deciphering its role in diabetes and its chronic complications. Clin. Exp. Pharmacol. Physiol., 2011, 38, 401-409.
90. Majumdar, S.; Buckles, E.; Estrada, J.; Koochekpour, S. Aberrant DNA methylation and prostate cancer. Curr. Genomics., 2011,12, 486-505.
91. Jones, P.A.; Takai, D. The role of DNA methylation in mammalian epigenetics. Science, 2001, 293, 1068-1070.
92. Olsen, A.S.; Sarras, M.P.; Leontovich, A.; Intine, R.V. Heritable transmission of diabetic metabolic memory in Zebrafish correlates with DNA hypomethylation and aberrant gene expression. Diabetes, 2012, 61, 485-491.
93. D'Souza, G.G.; Wagle, M.A.; Saxena, V.; Shah, A. Approaches for targeting mitochondria in cancer therapy. Biochim. Biophys. Acta., 2011, 1807, 689-696.
94. Wenner, C.E. Targeting mitochondria as a therapeutic target in cancer. J. Cell. Physiol., 2012, 227, 450-456.
95. Hammes, H.P.; Du, X.; Edelstein, D.; Taguchi, T.; Matsumura, T.; Ju ,Q.; Lin, J.; Bierhaus, A.; Nawroth, P.; Hannak, D.; Neumaier, M.; Bergfeld, R.; Giardino, I.; Brownlee, M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med., 2003, 9, 294-299.
96. Kowluru, R.A.; Odenbach, S. Effect of long-Term administration of alpha lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes, 2004, 53, 3233-3238.
97. Schen, T.; Chen, W.C.; Göllner, S.; Howell, L.; Jin, L.; Hebestreit, K.K.H.; Popescu, A.C.; Burnett, A.; Mills, K.; Casero, R.A.; Marton, L.; Woster, P.; Minden, M.D.; Dugas, M.; Wang, J.C.; Dick, J.E.; Müller-Tidow, C.; Petrie, K.; Zelent, A. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-Trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med., 2012, 18, 605-611.
98. Zhu, Q.; Huang, Y.; Marton, L.J.; Woster, P.M.; Davidson, N.E.; Casero, R.A.J. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids, 2012, 42, 887-898.
99. Williams, J.S.; Chamarthi, B.; Goodarzi, M.O.; Pojoga, L.H.; Sun, B.; Garza, A.E.; Raby, B.A.; Adler, G.K.; Hopkins, P.N.; Brown, N.J.; Jeunemaitre, X.; Ferri, C.; Fang, R.; Leonor, T.; Cui, J.; Guo, X.; Taylor, K.D.; Ida Chen, Y.D.; Xiang, A.; Raffel, L.J.; Buchanan, T.A.; Rotter, J.I.; Williams, G.H.; Shi, Y. Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive hypertension. Am. J. Hypertens, 2012, 25, 812-817.